SCHEMBL6341883

SCHEMBL6341883

CCCCCCCCCCCCOCC(O)COc1ccc(-c2nc(-c3ccc(-c4ccccc4)cc3)nc(-c3ccc(-c4ccccc4)cc3)n2)c(O)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PLA2G4B P0C869 2/20 0.46
PTPN11 Q06124 4/20 0.41
RARB P10826 3/20 0.39
CHRNA7 P36544 1/20 0.39
PTPN1 P18031 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
CNR2 P34972 2/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
MAPK10 P53779 1/20 0.37
CNR1 P21554 1/20 0.37
GPR55 Q9Y2T6 1/20 0.37
PLA2G10 O15496 1/20 0.37
PLA2G1B P04054 1/20 0.37
PLA2G2A P14555 1/20 0.37
PLA2G5 P39877 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6331891 1.00 PLA2G4B (0.46) PLA2G4BPTPN11RARBCHRNA7PTPN1
SCHEMBL6562548 0.98 PLA2G4B (0.47) PLA2G4BPTPN11PTPN1MAPTHTT
SCHEMBL6334661 0.97 PLA2G4B (0.41) PLA2G4BPTPN11RARBCHRNA7MAPT
SCHEMBL8383224 0.95 PLA2G4B (0.42) PLA2G4BPTPN11CHRNA7PTPN1MAPT
SCHEMBL8517433 0.95 PLA2G4B (0.42) PLA2G4BPTPN11CHRNA7PTPN1MAPT
SCHEMBL5645679 0.92 PLA2G4B (0.46) PLA2G4BPTPN11PTPN1MAPTHTT
SCHEMBL14112068 0.92 PLA2G4B (0.40) PLA2G4BPTPN11CHRNA7PTPN1MAPT
SCHEMBL6562204 0.92 PLA2G4B (0.42) PLA2G4BPTPN11RARBMAPTCNR2
SCHEMBL7254047 0.91 PLA2G4B (0.44) PLA2G4BPTPN11HTTCNR2PLA2G10
SCHEMBL8216433 0.91 LMNA (0.42) PLA2G4BMAPTHTTCNR2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120243115-A1 OPTICAL LAYERED BODY AND METHOD FOR PRODUCING OPTICAL LAYERED BODY DAI NIPPON PRINTING CO., LTD. (JP) 2012-09-27 US disclosed
US-20120243115-A1 OPTICAL LAYERED BODY AND METHOD FOR PRODUCING OPTICAL LAYERED BODY DAI NIPPON PRINTING CO., LTD. (JP) 2012-09-27 US disclosed
US-6919454-B2 Biphenyl-substituted triazines CIBA SPECIALTY CHEMICALS CORP. (US) 2005-07-19 US disclosed
US-20050019281-A1 Biphenyl-substituted triazines FLETCHER IAN JOHN (CH) 2005-01-27 US disclosed
US-6841670-B2 High thermal stability, are used as stabilizers for organic polymers to counter damage thereto caused by light, oxygen and heat, as light stabilizers for textile fiber materials and as sunscreens for the human skin. CIBA SPECIALTY CHEMICALS CORPORATION (US) 2005-01-11 US disclosed
US-20030045444-A1 Biphenyl-substituted triazines FLETCHER IAN JOHN (CH) 2003-03-06 US disclosed
US-6468958-B2 LIGHT, OXYGEN AND HEAT RESISTANCE CIBA SPECIALTY CHEMICALS CORPORATION 2002-10-22 US disclosed
EP-0815089-B1 BIPHENYL-SUBSTITUTED TRIAZINES AS LIGHT STABILIZER CIBA SC HOLDING AG (CH) 2002-09-25 EP disclosed
US-20010039341-A1 Biphenyl-Substituted Triazines FLETCHER IAN JOHN (CH) 2001-11-08 US disclosed
US-6255483-B1 USEFUL AS LIGHT STABILIZERS FOR TEXTILE FIBER MATERIALS AND SUNSCREENS FOR HUMAN SKIN CIBA SPECIALTY CHEMICALS CORPORATION 2001-07-03 US disclosed
US-5998116-A TRIAZINE UV ABSORBERS CIBA SPECIALTY CHEMICALS CORPORATION (US) 1999-12-07 US disclosed
US-5872116-A TREATMENT OF INFLAMATION, PAIN, MIGRAINE, ASTHMA AND EMESIS MERCK & CO., INC. (US) 1999-02-16 US disclosed
EP-0815089-A1 BIPHENYL-SUBSTITUTED TRIAZINES AS LIGHT STABILIZER Ciba SC Holding AG (CH) 1998-01-07 EP disclosed
WO-1996028431-A1 BIPHENYL-SUBSTITUTED TRIAZINES AS LIGHT STABILIZER CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 1996-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050019281-A1 Biphenyl-substituted triazines TYR, AHR, CUTA PLA2G4B 4540/4885PTPN11 1989/4885RARB 624/4885
US-20030045444-A1 Biphenyl-substituted triazines TYR, CYP1B1, NFE2L2 PLA2G4B 4570/4885PTPN11 2496/4885RARB 1218/4885
US-20010039341-A1 Biphenyl-Substituted Triazines TYR, CYP1B1, NFE2L2 PLA2G4B 4570/4885PTPN11 2496/4885RARB 1218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.